Affiliated Research Group:
Key Researcher(s):
Dr. Faleh Althiyabi
Dr. Ammar Alzaydi
Heart failure remains one of the most pressing medical challenges, affecting millions worldwide. While ventricular assist devices (VADs) have significantly improved survival rates for patients with systolic heart failure (HFrEF), no effective solution exists for diastolic heart failure (HFpEF), which accounts for 50% of the total heart failure cases. Researchers at KFUPM’s Interdisciplinary Research Center for Biosystems and Machines have developed PulseVAD, the first smart, AI-powered ventricular assist device specifically designed to address HFpEF, offers a groundbreaking alternative for patients with limited treatment options.
The PulseVAD system mimics normal heart physiology, integrating biocompatible, heat-resistant, and flexible leads to reduce infection risks while ensuring seamless implantation. Advanced smart sensors are designed to replicate natural heart rhythms, continuously monitoring physiological parameters and making real-time adjustments to optimize performance. The system is equipped with an automated, AI-driven heart-sensing controller, enabling personalized, adaptive therapy tailored to each patient’s unique condition. Additionally, remote monitoring capabilities allow for reduced hospital visits and lower healthcare costs, revolutionizing how heart failure patients are managed. A significant innovation in PulseVAD is its advanced lead development. The research team designed new lead configurations, offering enhanced flexibility and durability, minimizing the risk of mechanical failure. Comparative stress testing between older and newly developed leads demonstrates their superior resistance to kinking and breaking.
The impact of PulseVAD extends beyond individual patients. By providing an alternative to heart transplants, this technology has the potential to transform the global cardiovascular healthcare industry, making life-saving treatments more accessible. The device’s wearable and lightweight design allows for greater patient mobility and improved quality of life, while its energy-efficient operation minimizes complications associated with traditional cardiac support devices. The development of intelligent, AI-powered implantable biodevices represents a significant leap in medical technology, reinforcing Saudi Arabia’s commitment to leading biotechnology innovation by 2040.
Through our commitment to sustainable development, this project aligns with the following United Nations Sustainable Development Goals (SDGs):